Tumor metabolism: New opportunities for cancer therapy

Clinical and Translational Oncology

Volumn 8, Issue 10, 2006, Pages 711-716

  Mérida, Isabel ^a   Ávila Flores, Antonia ^b  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Akt; Cancer; Glycolysis; Metabolism; mTOR

Indexed keywords

GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE B;

ARTICLE; CANCER CELL; CANCER GENETICS; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CELL ENERGY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; EARLY DIAGNOSIS; GLUCOSE METABOLISM; GLYCOLYSIS; GROWTH REGULATION; HUMAN; MALIGNANT TRANSFORMATION; MAMMAL CELL; NONHUMAN; NUTRIENT; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; TUMOR; AEROBIC METABOLISM; ANIMAL; CELL; COMPARATIVE STUDY; ENERGY METABOLISM; GENETICS; METABOLISM; MUTATION; NEOPLASM; PROTEIN SYNTHESIS; REVIEW; SCINTISCANNING; TIME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AEROBIOSIS; ANIMALS; CELLS; ENERGY METABOLISM; GLYCOLYSIS; HUMANS; MUTATION; NEOPLASMS; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TIME FACTORS;

EID: 34250879525     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0117-6     Document Type: Article

References (27)

1. Hanahan D, Weinberg R. The hallmarks of cancer. Cell, 2000;100:57-70.
2. Hammerman P, Fox C, Thompson C. Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci. 2004;15:259-66.
3. Warburg O. On the origin of cancer cells. Science, 1956;123:309-14.
4. Gambhir S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer, 2002;2:683-93.
5. Baysal B, Ferrell R, Willett-Brozick J, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 2000;287:848-51.
6. Tomlinson I. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Gen. 2002;30:406-10.
7. Selak M, Armour S, MacKenzie E, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77-85.
8. Semenza G. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol Med. 2001;7:345-50.
9. Semenza G. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003;3:721-32.
10. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873-7.
11. Fresno Vara J, Casado E, de Castro, J, et al. P13K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30:193-204.
12. Engelman J, Luo J, Cantley L. The evaolution of P13 kinases as regulators of growth and metabolism. Nat Review Genet. 2006;441:606-19.
13. Majewski N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell. 2004;16:819-30.
14. Kahn B, Alquier T, Carling D, et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
15. Jones R, Plas D, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18:283-93.
16. Corradetti M, Inoki K, Bardeesy N, et al. Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 2004;18:1533-8.
17. Wullschlege R, Loewith R, Hall M. TOR signaling in growth and metabolism. Cell. 2006;124:471-84.
18. Li Y CM, Inoki K, Guan KL. TSC2: Filling the GAP in the mTOR signaling pathway. Trends Biochem Sci. 2004;29:32-8.
19. Manning B, Cantley L. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28:573-6.
20. Inoki K, Zhu T, Guan K. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577-90.
21. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893-904.
22. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov, 2006;2:132-4.
23. Kondoh H, Lleonart M, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005;65:177-85.
24. Kim JW, Dang CV: Multifaceted roles of glycolytic enzymes. Trends Biochem Sci. 2005;30:142-50.
25. Gottlob K, Majewski N, Kennedy S, et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15:1406-18.
26. Sun Y, Chou C, Chen W, et al. The crystal structure of a multifunctional protein: Phosphoglucose isomerase/autocrine motility factor/neuroleukin. Proc Natl Acad Sci USA. 1999;96:5412-7.
27. Zheng L, Roeder R, Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell Metab. 2003;114:255-66.